01 / DESIGN
What was studied?
Investigators randomized 508 patients with predicted severe acute necrotizing pancreatitis to thymosin alpha 1 or placebo. Most required intensive care. The main outcome was infected pancreatic necrosis during the index admission.
02 / FINDINGS
What did the researchers report?
The complication occurred in 15.7% of the active-treatment group and 18.1% of the placebo group. The difference was not statistically significant, and major secondary complications did not show a clear group difference.
03 / LIMITS
How should it be interpreted?
This negative primary result should remain visible when evaluating the research record. It concerns a defined, severely ill hospital population, not healthy users. Neither the numerical difference nor a mechanistic rationale establishes a clinical benefit.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.